Toxicology Unit, Medical Research Council, Lancaster Road, Leicester, UK.
Lancet Oncol. 2012 Jun;13(6):e249-58. doi: 10.1016/S1470-2045(12)70073-6.
Since the identification of microRNAs (miRNAs) in 1993, and the subsequent discovery of their highly conserved nature in 2000, the amount of research into their function--particularly how they contribute to malignancy--has greatly increased. This class of small RNA molecules control gene expression and provide a previously unknown control mechanism for protein synthesis. As such, it is unsurprising that miRNAs are now known to play an essential part in malignancy, functioning as tumour suppressors and oncogenes. This Review summarises the present understanding of how miRNAs operate at the molecular level; how their dysregulation is a crucial part of tumour formation, maintenance, and metastasis; how they can be used as biomarkers for disease type and grade; and how miRNA-based treatments could be used for diverse types of malignancies.
自 1993 年鉴定出 microRNAs(miRNAs),以及 2000 年发现其高度保守性质以来,对其功能的研究——特别是它们如何促进恶性肿瘤——大大增加了。这类小分子 RNA 控制基因表达,并为蛋白质合成提供了一个以前未知的控制机制。因此,miRNAs 现在被认为在恶性肿瘤中起着至关重要的作用,作为肿瘤抑制因子和癌基因发挥作用,这并不令人惊讶。这篇综述总结了目前对 miRNA 在分子水平上的作用机制的理解;它们的失调是肿瘤形成、维持和转移的关键部分;它们如何被用作疾病类型和分级的生物标志物;以及基于 miRNA 的治疗方法如何用于多种类型的恶性肿瘤。